Genesee Capital Advisors LLC bought a new position in shares of Danaher Co. (NYSE:DHR) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 9,870 shares of the conglomerate’s stock, valued at approximately $3,005,000. Danaher makes up approximately 1.5% of Genesee Capital Advisors LLC’s portfolio, making the stock its 17th largest position.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in DHR. Stonehage Fleming Financial Services Holdings Ltd bought a new stake in Danaher during the second quarter worth about $26,000. GPS Wealth Strategies Group LLC raised its holdings in Danaher by 146.3% during the second quarter. GPS Wealth Strategies Group LLC now owns 101 shares of the conglomerate’s stock worth $27,000 after acquiring an additional 60 shares in the last quarter. McCarthy Asset Management Inc. bought a new stake in Danaher during the second quarter worth about $27,000. Alaethes Wealth LLC bought a new stake in Danaher in the second quarter valued at approximately $32,000. Finally, Penserra Capital Management LLC bought a new stake in Danaher in the second quarter valued at approximately $40,000. Institutional investors and hedge funds own 88.49% of the company’s stock.
In other Danaher news, Chairman Mitchell P. Rales sold 343,861 shares of the firm’s stock in a transaction on Tuesday, November 2nd. The stock was sold at an average price of $312.94, for a total value of $107,607,861.34. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Chairman Mitchell P. Rales sold 343,862 shares of the firm’s stock in a transaction on Thursday, November 4th. The shares were sold at an average price of $305.85, for a total value of $105,170,192.70. The disclosure for this sale can be found here. In the last ninety days, insiders sold 694,908 shares of company stock worth $214,929,432. Company insiders own 11.40% of the company’s stock.
Shares of NYSE:DHR opened at $315.48 on Thursday. The company has a market capitalization of $225.43 billion, a P/E ratio of 39.98, a P/E/G ratio of 2.35 and a beta of 0.70. Danaher Co. has a 1 year low of $211.22 and a 1 year high of $333.96. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.48 and a quick ratio of 1.11. The business’s 50 day simple moving average is $308.25 and its 200 day simple moving average is $292.45.
Danaher (NYSE:DHR) last issued its quarterly earnings results on Wednesday, October 20th. The conglomerate reported $2.39 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.15 by $0.24. The business had revenue of $7.20 billion for the quarter, compared to the consensus estimate of $7 billion. Danaher had a return on equity of 18.32% and a net margin of 20.97%. The firm’s quarterly revenue was up 22.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.72 earnings per share. On average, sell-side analysts anticipate that Danaher Co. will post 9.8 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Friday, October 29th. Shareholders of record on Thursday, September 30th were issued a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.27%. The ex-dividend date of this dividend was Wednesday, September 29th. Danaher’s dividend payout ratio is presently 10.65%.
Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial, and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines.
Featured Article: What are the benefits of a balanced fund?
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.